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Measure Hematocrit to Determine
ECV Fraction?*
David A. Bluemke, MD, PHD, Nadine Kawel-Boehm, MDF ocal ﬁbrosis, most due to myocardial infarc-tion, is readily identiﬁed by cardiac magneticresonance (CMR) using widely validated late
gadolinium enhancement methods. However, many
common conditions of the heart, ranging from hyper-
trophic cardiomyopathy to idiopathic dilated
cardiomyopathy or myocarditis, are histologically
characterized by diffuse, interstitial myocardial
ﬁbrosis. In these conditions, “T1 mapping” may be
used to determine abnormalities in the T1 relaxivity
of the myocardium either before or after administra-
tion of a gadolinium-based CMR contrast agent (1).
The term T1 mapping involves measuring the T1
time, or spin-lattice relaxation time, on a pixel-by-
pixel basis over the entire image ﬁeld of view. The
T1 relaxation time is the time (in milliseconds) for a
tissue to obtain approximately 63% of its longitudinal
relaxation (parallel to the main magnetic ﬁeld). Most
current magnetic resonance imaging (MRI) scanners
include software that allows routine measurement
of T1 time for each pixel in a slice of tissue, thus
providing a “map” of myocardial T1 times. For refer-
ence, the normal T1 time of the heart is approximately
1,000 ms at 1.5-T (2). For comparison, the T1 time of
fat (250 ms) is much shorter than myocardium,
whereas the T1 time of blood is approximately 1,400
ms. The T1 time of blood depends on temperature,ECVmyocardium ¼
ð1  hematocritÞ 
h
ð1=T1Þmyh
ð1=T1Þblood pos
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The term “native T1 time” has been used in the CMR
literature when referring to noncontrast CMR images.
When the myocardium is replaced by diffuse ﬁbrosis,
the native T1 time increases slightly, for example, by
10% to 20% (e.g., dilated and hypertrophic cardiomy-
opathy (4), whereas post-gadolinium T1 time de-
creases also by 10% to 20%or so. However, change in T1
time is not speciﬁc for ﬁbrosis. Both the native and
post-gadolinium T1 times of the myocardium are also
altered by other substrates that might occur in the
myocardial interstitial space such as edema, lipid (as in
Anderson-Fabry disease [5]), iron, or amyloid (6).
The T1 time is reﬂective of the composite status of
both myocytes and interstitium. Using CMR, the
extracellular volume (ECV) of the myocardium may be
estimated bymeasuring pre- and post-contrast T1 time
of blood and myocardium and the hematocrit. The
concentration of gadolinium is directly related to the
difference between pre-contrast and post-contrast
reciprocal values of T1 (T1 ¼ 1/R1, where R indicates
relaxivity), leading to the following equation (7,8):
ECVmyocardium = DR1myocardium ¼ ECVblood = DR1blood
Because the ECV of blood is (1  hematocrit), ECV of
myocardium can be calculated as follows:ocardium post-contrast  ð1=T1Þmyocardium pre-contrast
i
t-contrast  ð1=T1Þblood pre-contrast
iwhere hematocrit is expressed as a fraction between
0 and 1. As a percentage of tissue volume, the normal
ECV of the myocardium ranges from about 21% to
31%, with a mean of about 25% to 26% (9). Elevated
ECV values have been reported in both primary and
systemic cardiac disease, including dilated and
hypertrophic cardiomyopathy, aortic stenosis, car-
diac AL amyloidosis, and myocardial infarction (10).
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65ECV is reported to be elevated in hypertrophic car-
diomyopathy sarcomere mutation carriers even in the
absence of left ventricular hypertrophy (11), indi-
cating its value in early disease detection before
clinical manifestation. ECV may also be useful to
assess cardiotoxicity from anthracycline-based
chemotherapy (12) or to monitor therapy success
of ﬁbrosis-modulating therapies such as renin-
angiotensin antagonists. ECV has been shown to
predict all-cause mortality in certain populations (13).
ECV has also been identiﬁed as a viable surrogate
marker of extracellular matrix expansion in research
applications for heart failure (14).
An obstacle in CMR studies in determining
myocardial ECV has been determining the hematocrit
value (15). The hematocrit can be performed by
inexpensive laboratory equipment incorporating op-
tical or electrical methods and typically costs on the
order of $10 to $30 per test; point-of-care testing costs
are about $1 each test kit. The hematocrit may be
obtained along with laboratory tests of renal function
before CMR, but not all patients require renal func-
tion tests. For stable outpatients, renal function lab-
oratory values are accepted to be representative of
renal status for up to 30 days before CMR examina-
tion, but hematocrit values may ﬂuctuate markedly
during this period.SEE PAGE 54In this issue of iJACC, Treibel et al. (16) propose
that hematocrit values may be derived directly from
blood measurements during the CMR examination
itself. This would provide great efﬁciency for ECV
determination by CMR. The authors plotted labora-
tory determined hematocrit versus relaxivity (R1)
of blood determined by 2 different CMR pulse
sequences (MOdiﬁed Look-Locker Inversion recovery
and Shortened MOdiﬁed Look-Locker Inversion re-
covery) in 213 study subjects. R1 was linearly related
to hematocrit with a correlation coefﬁcient of 0.51
(MOdiﬁed Look-Locker Inversion recovery) and 0.45
(Shortened Modiﬁed Look-Locker Inversion recov-
ery). Interestingly, despite these relatively low
correlation coefﬁcients, ECV using conventional
hematocrit measure was closely related to ECV using
a CMR “synthetic” hematocrit derived directly from
the images (R2 ¼ 0.97). The difference between ECV
by CMR versus conventional ECV was within about
10% of the mean ECV in 95% of cases. Thus, for
practical purposes, the CMR “synthetic” ECV and the
conventionally determined ECV were interchange-
able: Treibel et al. (16) demonstrated this by showing
nearly identical correlation coefﬁcients between ECV
with either method and collagen volume fraction in18 patients with aortic stenosis. Similarly, both syn-
thetic and conventional ECV were equally well
related to risk of hospitalization for heart failure or
death in 1,172 subjects.
It seems peculiar that despite low agreement be-
tween CMR hematocrit and conventional hematocrit
(R2 ¼ 0.45 to 0.51), ECV by CMR hematocrit correlated
very well with ECV by conventional hematocrit
(R2 ¼ 0.97). The reasons for this are not readily
explained by the provided data. One possibility is that
the hematocrit varies over a relatively small range (by
a factor of 1.4, from 35% to 48%, Treibel et al. [16]
Figure 1), whereas ECV varied by a factor of 4-fold in
their patients (about from 20% to 80%, Treibel et al.
(16) Figure 2). Thus, terms other than hematocrit in
the ECV equation may outweigh small variations in
hematocrit. Indeed, very high values of ECV greater
than about 0.45 are usually seen in focal myocardial
scar—focal scar cases are not typically those situations
where ECV is of great value. In this regard, ECV, a
complex ratio, simply does not change much in the
presence of large amounts of diffuse ﬁbrosis: for
example, the data of Treibel et al. (16) show that
despite 400% variation in collagen fraction in aortic
stenosis patients (from 10% to 40%), the ECV only
changes by a factor of about 60% (from 0.25 to 0.4).
CMR researchers and clinicians may wish to
instantly switch to the “synthetic” ECV method
proposed by Treibel et al. (16) on the basis of these
results. Unfortunately, there are several caveats that
need further assessment. First, their results apply
only to the Siemens pulse sequence software MRB17
using pulse sequence parameters shown in the data
supplement provided by the authors. Calibrations for
other pulse sequences will need similar validation.
Also, the results of Treibel et al. have only been
validated at 1.5-T CMR; at 3.0-T MRI, there are
signiﬁcant differences in arterial and venous T1
values by CMR (17). The unexpectedly low correlation
of conventional and CMR determined hematocrit
needs further explanation. Flow artifacts on CMR in
the ventricular cavity could cause unexpected varia-
tions. Also, the authors show unexpectedly low test/
retest results for conventional hematocrit of 10% for
blood samples taken with a median time delay of 4 h.
However, in the literature, a high precision for
hematocrit measurements is reported. The coefﬁcient
of variation of 1.1% for measurements for standard
laboratory assays of hematocrit has been reported
(18). Signiﬁcant diurnal, postural, and post-prandial
variation of the hematocrit has been demonstrated
as well as changes with hydration and exercise
(19,20). The median time delay of 4 h in test/retest
for hematocrit in the current study might explain
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66the variation of the measurements of conventional
hematocrit.
Ordinarily, we would not think of using an
approximately $1.5 million CMR scanner to replace a
several thousand dollar, highly accurate piece of
laboratory equipment to measure hematocrit. Treibel
et al. (16), however, have convincingly shown that
either method works equally well in their hands and
can provide excellent efﬁciencies for CMR assessment
of diffuse ﬁbrosis. This study also reinforces that the
conventional hematocrit should be obtained in close
proximity to the time of the actual CMR scan to pro-
vide best accuracy. For research studies where blood
tests are already routinely being obtained, it seems
prudent to continue to obtain gold standard hemat-
ocrit values when feasible in order to reduce error inCMR ECV values. CMR is the only noninvasive tech-
nique that has been shown to provide an index of
diffuse myocardial ﬁbrosis, so the work of Treibel
et al. (16) is likely to greatly enhance CMR research
studies of cardiomyopathy. The approach of Treibel
et al. (16) may also ultimately provide a means to
bridge the results of research studies to clinical ap-
plications when determination of extracellular vol-
ume fraction is of value for clinical decision making.
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